Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BGF MDI HFO
- Development stage
- Phase 3
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
BGF MDI HFO is a fixed-dose triple-combination therapy developed by AstraZeneca for the treatment of chronic obstructive pulmonary disease (COPD). It consists of budesonide (an inhaled corticosteroid), glycopyrronium bromide (a long-acting muscarinic antagonist), and formoterol fumarate (a long-acting beta-2 agonist). This formulation is delivered via a pressurized metered-dose inhaler (pMDI) using the next-generation hydrofluoroolefin (HFO) propellant, HFO-1234ze(E), which has a 99.9% lower global warming potential compared to traditional hydrofluoroalkane (HFA) propellants. The therapy provides a comprehensive approach to COPD management by combining anti-inflammatory effects with dual bronchodilation. It is currently being evaluated in Phase I bioequivalence studies to support the transition of AstraZeneca's respiratory portfolio to more environmentally sustainable propellants.
- Brand names
- Breztri AerosphereTrixeo Aerosphere
- Other names
- Budesonide/glycopyrronium/formoterol fumarate HFOBGF HFO
02
Targets
GR (Glucocorticoid receptor)CHRM3 (M3)ADRB2 (β2)
Beyond the preview
Go deeper on BGF MDI HFO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BGF MDI HFO.